Repligen Corporation (RGEN)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $10.73B
Last updated: Nov 17, 2026 at 11:06 AM ET
Repligen Corporation (RGEN) P/E Ratio & Valuation History
Repligen (RGEN) trades at 79.8x trailing earnings and 11.4x sales. Its P/E of 79.8x is below its 5-year median of 83.5x. Its forward P/E is 60.2x. The median P/E across 11 similar companies is 20.7x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 32.6% higher over the next year. Its free cash flow yield is 1.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 79.8x |
| Forward P/E | 60.2x |
| Price to sales | 11.4x |
| Price to book | 4.4x |
| EV/EBITDA | 91.0x |
| Price to FCF | 86.3x |
| EV/FCF | 84.7x |
| PEG | 1.6 |
| FCF yield | 1.2% |
Historical Medians
Against its 10-year medians, its P/E is 3.4% below 82.6x, its P/S is 13.6% below 13.2x and its P/B is 8.3% below 4.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 79.8x | 83.5x | 82.6x |
| P/S | 11.4x | 12.8x | 13.2x |
| P/B | 4.4x | 4.7x | 4.8x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 51.6x in 2022 to 138.6x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $163.86 | 95.8x | 12.5x | 4.4x |
| 2024 | $143.94 | 138.6x | N/A | 4.1x |
| 2023 | $179.80 | 103.9x | 15.8x | 5.1x |
| 2022 | $169.31 | 51.6x | 11.8x | 5.1x |
| 2021 | $264.84 | 86.5x | 22.0x | 8.7x |
| 2020 | $191.63 | 115.4x | 27.8x | 6.9x |
| 2019 | $92.50 | 88.1x | 16.6x | 4.6x |
| 2018 | $52.74 | 71.3x | 11.9x | 4.0x |
| 2017 | $36.28 | 51.8x | 9.9x | N/A |
| 2016 | $30.82 | 70.0x | 5.0x | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RGEN
What is RGEN's forward P/E ratio?
Repligen has a forward P/E ratio of 60.2x.
Is RGEN stock overvalued?
GNG's valuation label for RGEN is Undervalued. Its P/E of 79.8x compares with a median of 20.7x across 11 similar companies.
What is RGEN's price to sales ratio?
Repligen has a price to sales ratio of 11.4x.
What is Repligen's average P/E ratio over 5 years?
Repligen's median P/E over the last 5 years is 83.5x, from 60 month-end values through Oct 2026.
What is RGEN's PEG ratio?
Repligen has a PEG ratio of 1.6.
RGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts